Researchers have identified a mechanism through which Lymphocyte Activation Gene 3 (LAG-3), a key immunosuppressive receptor, suppresses T cell activity—not by ligand binding alone, but by spatial ...

TCR-T increases the flexibility for targeting solid tumours, particularly those with a high mutational burden (HMB). Unlike TILs, one does not need access to the primary tumour, which allows the use ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Cancer immunotherapies widely rely on T cells. In order to become active, T cells interact via their receptors with the major histocompatibility complex (MHC), which expresses fragments of ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...